The effect ofmidazolam and anxiety on amnesia

Phase 3

• Conditions: anxiety.; Generalized anxiety disorder; F41.1

• Registration Number: IRCT20200213046484N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

120 patients aged 20 to 60 years at risk of ASA1-2 undergoing non-emergency abdominal laparotomy undergoing GA at Rasool Akram Hospital

Exclusion Criteria

Patients with ASAIII risk
The Pregnant patient
Patients with psychiatric disorders or receiving sedative and antipsychotic medications
Mental dysfunction
Patients with visual or hearing impairment
Patients with liver and kidney dysfunction
Previous use of benzodiazepine

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Amnesia. Timepoint: Zero minutes (4 min before premedication), 2 (2 min before premedication), 4 (immediately before premedication) 6 min (2 min after premedication), 8 (4 min after Premedication) and 10 (6 min after premedication. Method of measurement: Cards with simple photos.

Secondary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: minutes 1,2,3 after intubation. Method of measurement: NIBP.;Heart rate. Timepoint: Minutes 1,2,5after intubation. Method of measurement: Monitoring device.;Decrease in oxygen saturation. Timepoint: Minutes 1,2,5after intubation. Method of measurement: Pulse oximetry.